Physician profile
Daniel J Ha
NPI 1023503984
$1,752.50
in general payments reported to CMS, 2019-2025
15 companies · $820 in 2025
The $820 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $52.39 · 2023: $362 · 2024: $518 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,624 · Education: $75.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,624.45 |
| Education | $75.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $401.45 | 2022-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $315.56 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $228.57 | 2023-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $120.57 | 2023-2024 | Quviviq |
| Axsome Therapeutics, INC. | $110.06 | 2024-2025 | Auvelity |
| Abbvie INC. | $107.90 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $105.39 | 2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $81.63 | 2022-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $66.94 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $50.33 | 2024-2025 | Austedo Xr, Austedo Xr |
| Noven Therapeutics, LLC | $47.14 | 2024-2025 | Xelstrym |
| Neurocrine Biosciences, INC. | $40.99 | 2023 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.84 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $21.05 | 2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $16.08 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.